Navigation Links
JHP Pharmaceuticals to Produce Clinical Batches of Innovative Cardiac Drug
Date:7/25/2011

PARSIPPANY, N.J., July 25, 2011 /PRNewswire/ -- JHP Pharmaceuticals, a leading provider of contract manufacturing services for sterile injectable products has entered into an agreement with an undisclosed biotech company to produce clinical trial batches of an innovative drug used in the treatment of heart failure.

Stuart Hinchen, President and CEO of JHP stated, "We are pleased that JHP was chosen to produce clinical batches for this important customer. Our cGMP compliance record, coupled with an experienced staff, gives us an advantage in meeting customer needs throughout a product's life cycle, starting with clinical batch production."

"We know that customers want to seamlessly transition from clinical batch production to product launch and then commercialization. JHP has the right scale and experience to meet customer needs across the product life cycle."

Hinchen also noted, "During the last seven months, we successfully completed FDA and EMA audits and entered agreements with five new customers. These agreements are examples of how our approach to continuing investment allows us to focus on customer needs, which results in an internal infrastructure that supports ongoing sustainable growth."

JHP's Rochester, Michigan manufacturing site has a solid history of successful partnerships, manufacturing clinical and commercial products.

About JHP Pharmaceuticals, LLC JHP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile injectables and ophthalmic/otic products, for large and small pharmaceutical and biotech organizations.

JHP's sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse. The production facility utilizes three high-speed filling lines, a clinical filling line, four lyophilizers and an ophthalmic filling line. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development.

JHP has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 330 staff in the USA in its manufacturing, product development, sales & marketing and corporate areas. For more information, please visit www.jhppharma.com. Contact: Dan Leone 973.658.3559 Bill Conway 877.906.7556 jhpcontractservices@jhppharma.com MK249
'/>"/>

SOURCE JHP Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
2. Valeant Pharmaceuticals Announces Approval of Sublinox® in Canada
3. Merz Pharmaceuticals Commends The Benign Essential Blepharospasm Research Foundation On 30 Years Of Community Support
4. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
5. Vanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
6. ReportsnReports - The Outlook for Pharmaceuticals (BRIC, Asia, Europe, E7)
7. Amylin Pharmaceuticals to Webcast Second Quarter Results
8. Valeant Pharmaceuticals Announces Distribution Agreement for Zuacta™ in Canada
9. Access Pharmaceuticals MuGard Included in TRICARE Prescription Drug Coverage
10. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
11. Valeant Pharmaceuticals Agrees to Acquire Ortho Dermatologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... 19, 2016 A new report ... Market -Opportunities and Forecasts, 2015 -2022, projects that the ... 2022, registering a CAGR of 5.1% from 2015 to ... be the highest revenue-generating segment throughout the forecast period. ... one-third of the market share in 2015, and is ...
(Date:5/19/2016)... -- The equities market is never short of ... is without doubt the Healthcare space. ActiveWallSt.com has uncovered four ... Alkermes PLC (NASDAQ: ALKS ), AMAG Pharmaceuticals Inc. ... IDXX ), and Atossa Genetics Inc. (NASDAQ: ... http://www.activewallst.com/ On Wednesday, Alkermes PLC,s ...
(Date:5/19/2016)... 19, 2016 MGB Biopharma, ... of Anti-infectives, Welcomes the Final Instalment of Lord ... Today   Lord Jim O,Neill,s ... final recommendations, providing a comprehensive action plan for ... the rising threat of superbugs - something that ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... The old expression “a ... problem. A common injury that’s often misunderstood, whiplash should be swiftly diagnosed and treated ... orthopedic spine surgeon at Atlantic Spine Center . , So named because ...
(Date:5/24/2016)... ... 24, 2016 , ... Researchers from Catholic Health Initiatives (CHI) ... bleeding complications from percutaneous coronary intervention (PCI). The data, presented at the annual ... document a 40% reduction in risk-adjusted bleeding event rates over a two-year period ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... web-based software module. The cutting-edge feature provides end users with an embedded, ... self-service business intelligence solution and its analytics engine. , This powerful ...
(Date:5/23/2016)... Akron, Ohio (PRWEB) , ... May 23, 2016 ... ... not-for-profit continuing care retirement community, dedicated its new $11.5 million, 64-room assisted living ... an invitation-only ceremony and ribbon cutting. , The new building provides the ...
(Date:5/23/2016)... ... May 23, 2016 , ... According to an article ... than 1% of United Kingdom residents who could benefit from bariatric surgery are actually ... increases the number of bariatric procedures it offers to obese patients from 6,000 to ...
Breaking Medicine News(10 mins):